Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open-label, phase i study

Journal of Clinical Pharmacology

Volumn 54, Issue 11, 2014, Pages 1308-1317

  Petersenn, Stephan ^a   Bollerslev, Jens ^b   Arafat, Ayman M ^c   Schopohl, Jochen ^d   Serri, Omar ^e   Katznelson, Laurence ^f   Lasher, Janet ^g   Hughes, Gareth ^g   Hu, Ke ^g   Shen, George ^g   Reséndiz, Karina Hermosillo ^g   Giannone, Vanessa ^g   Beckers, Albert ^h  

^a ENDOC Center for Endocrine Tumors   (Germany)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

^h UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

acromegaly; pasireotide (SOM230); pharmacodynamics; pharmacokinetics; safety

Indexed keywords

GROWTH HORMONE; HEMOGLOBIN A1C; PASIREOTIDE; SOMATOMEDIN C; GLUCOSE BLOOD LEVEL; SOMATOSTATIN;

ACROMEGALY; ADULT; ADVERSE OUTCOME; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; HALF LIFE TIME; HOMEOSTASIS; MIDDLE AGED;

ACROMEGALY; ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HOMEOSTASIS; HUMANS; MALE; MIDDLE AGED; SOMATOSTATIN;

EID: 84925468312     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.326     Document Type: Article

References (19)

1. Chanson P, Salenave S,. Acromegaly. Orphanet J Rare Dis. 2008; 3: 17.
2. Melmed S,. Medical progress: acromegaly. N Engl J Med. 2006; 355: 2558-2573.
3. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009; 94: 1509-1517.
4. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G,. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002; 146: 707-716.
5. Colao A, Petersenn S, Newell-Price J, et al. A 12-month Phase 3 study of pasireotide in Cushing's disease. N Engl J Med. 2012; 366: 914-924.
6. Beglinger C, Hu K, Wang Y, et al. Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study. Endocrine. 2012; 42: 366-374.
7. Golor G, Hu K, Ruffin M, et al. A first-in-man study to evaluate the safety, tolerability and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther. 2012; 6: 71-79.
8. Petersenn S, Hu K, Maldonado M, et al. Tolerability and dose-proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study. Clin Ther. 2012; 34: 677-688.
9. Lin TH, Hu K, Flarakos J, et al. Assessment of the absorption, metabolism and excretion of [(1)(4)C]pasireotide in healthy volunteers using accelerator mass spectrometry. Cancer Chemother Pharmacol. 2013; 72: 181-188.
10. Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, Phase II trial. J Clin Endocrinol Metab. 2010; 95: 2781-2789.
11. Dietrich H, Hu K, Ruffin M, et al. Safety, tolerability and pharmacokinetics of a single dose of pasireotide long-acting release (LAR) in healthy volunteers: a single-center Phase I study. Eur J Endocrinol. 2012; 166: 821-828.
12. National Cancer Institute,. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf; 2006.
13. Wolin EM, Hu K, Hughes G, Bouillaud E, Giannone V, Resendiz KH,. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study. Cancer Chemother Pharmacol. 2013; 72: 387-395.
14. Kvols LK, Oberg KE, O'Dorisio TM, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a Phase II study. Endocr Relat Cancer. 2012; 19: 657-666.
15. Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014; 99: 791-799.
16. Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary dependent Cushing's disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab. 2009; 94: 115-122.
17. Petersenn S, Unger N, Hu K, et al. Pasireotide (SOM230), a novel multi-receptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers. J Clin Pharmacol. 2012; 52: 1017-1027.
18. Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S,. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013; 98: 3446-3453.
19. Breitschaft A, Hu K, Hermosillo RK, Darstein C, Golor G,. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract. 2014; 103: 458-465.